logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
M

Mahadi Baig

Johnson & Johnson
H指数:15
被引数:1,153

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Amivantamab plus chemotherapy vs. chemotherapy as first-line treatment in Chinese mainland patients with EGFR exon 20 insertion non-small cell lung cancer: Subgroup analysis of the randomized PAPILLON trial

中国大陆EGFR外显子20插入突变非小细胞肺癌患者中，阿曼曲单抗联合化疗与化疗作为一线治疗的比较：随机PAPILLON试验的亚组分析

Chinese Medical Journal
IF7.3
2026-05-260
OA
Tang, Kejing; Wu, Fengying; Yang, Fang; Yao, Yu; Zhao, Yanqiu; Zhou, Jianying; Sun, Ping; Wang, Donglin; Lv, Dongqing; Wang, Huijie; Hu, Yi; Li, Qiang; Song, Yujiao; Gao, Grace; Pan, Fang; Bhattacharya, Archan; Baig, Mahadi; Lorenzini, Patricia A.; Wortman-Vayn, Honeylet; Agrawal, Trishala; Zhou, Caicun
Development of the Weight-Tiered Q3W Regimen of Amivantamab in Combination With Carboplatin-Pemetrexed in EGFR-Mutated Non-Small Cell Lung Cancer

EGFR突变非小细胞肺癌中阿曼曲妥珠单抗联合卡铂-培美曲塞的体重分级Q3W方案的开发

cpt: pharmacometrics & systems pharmacology
IF0
2026-05-210
OAAI
Dongfen Yuan; Corey J. Bishop; Jaydeep Mehta; Wangda Zhou; Lu Zhang; Jie Zhou; Raja Venkatasubramanian; Alex Yu; Trishala Agrawal; Sujay Shah; Mahadi Baig; Joshua M. Bauml; Pritam Kambuj; Lahila-Carina Ojeda; Pamela L. Clemens; Nahor Haddish-Berhane; Yaming Su; Mahesh Samtani
Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis

Amivantamab联合化疗与化疗一线治疗EGFR外显子20插入突变的晚期非小细胞肺癌患者: PAPILLON Asia亚组分析

Lung Cancer
IF4.4
2026-02-020
PRE
Caicun Zhou; Ke-Jing Tang; Baogang Liu; Sang-We Kim; Satoru Kitazono; Akira Ono; Muthukkumaran Thiagarajan; Jen-Yu Hung; Michael Boyer; Timuçin Çİl; Yu Yao; Rajnish Nagarkar; John Xie; Archan Bhattacharya; Honeylet Wortman-Vayn; Mahadi Baig; Trishala Agrawal; Patricia Lorenzini; Se-Hoon Lee; Byoung Chul Cho
Subcutaneous amivantamab in recurrent/metastatic head and neck squamous cell cancer after disease progression on checkpoint inhibitor and chemotherapy: Preliminary results from the phase 1b/2 OrigAMI-4 study

皮下注射阿曼曲单抗在复发性/转移性头颈鳞状细胞癌中的应用：在免疫检查点抑制剂和化疗后疾病进展的患者中的初步结果，来自OrigAMI-4研究（1b/2期）

Oral Oncology
IF3.9
2025-11-220
OAAI
Kevin J. Harrington; Ari J. Rosenberg; Muh-Hwa Yang; Jessica L. Geiger; Marc Oliva; Myung-Ju Ahn; Sun Min Lim; William Ince; Aarti Bhatia; Siddharth Sheth; Bhumsuk Keam; Robert Metcalf; Joshua C. Curtin; Kiichiro Toyoizumi; Mark Wade; Emrullah Yilmaz; Priya Kim; Remy B. Verheijen; Sujay Shah; Mahadi Baig
Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study

Amivantamab-化疗在EGFR外显子20插入的非小细胞肺癌中的应用：来自III期PAPILLON研究的治疗交叉和其他终点的影响

Targeted Oncology
IF4
2025-11-030
OAAI
Rachel E. Sanborn; Caicun Zhou; Ke-Jing Tang; Byoung Chul Cho; Susanna Cheng; Sanjay Popat; Akira Ono; Shun Lu; Margarita Majem; Andres Aguilar; Maria Del Rosario Garcia Campelo; Hidetoshi Hayashi; Kang-yun Lee; Se-Hoon Lee; Angelo Delmonte; Jorge Alatorre-Alexander; Gary Richardson; Victor Santos; Christophe Dooms; Joshua K. Sabari; Catherine A. Shu; Nicolas Girard; Aaron S. Mansfield; Keunchil Park; Yichuan Xia; Archan Bhattacharya; Nasuh Buyukkaramikli; Nolen Perualila; Joris Diels; Sandip Acharya; Conor Chandler; Irina Proskorovsky; Lindsay Dearden; Honeylet Wortman-Vayn; Parthiv J. Mahadevia; Roland E. Knoblauch; Trishala Agrawal; Mahadi Baig; Enriqueta Felip
Erdafitinib in Patients with High- and Intermediate-risk Non–muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study

厄达菲尼布治疗高危和中等风险非肌层浸润性膀胱癌患者：THOR-2研究的最终分析

European Urology
IF25.2
2025-10-070
OAAI
Siamak Daneshmand; Renata Zaucha; James W.F. Catto; Ben Tran; Viraj Master; Yair Lotan; Geraldine Pignot; Andrea Tubaro; Nobuaki Shimizu; Nikhil Vasdev; Eugene K. Lee; Giuseppe Procopio; Fernando Galanternik; Lauren Crow; Kris Deprince; Vahid Naini; Spyros Triantos; Mahadi Baig; Wei Zhu; Jodi K. Maranchie
Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC

患者报告结局和症状进展时间来自PAPILLON研究：amivantamab联合化疗对比化疗作为表皮生长因子受体（EGFR）外显子20插入突变型晚期非小细胞肺癌的一线治疗

Lung Cancer
IF4.4
2025-10-030
PRE
Luis Paz-Ares; Remi Veillon; Margarita Majem; Caicun Zhou; Ke-Jing Tang; Sang-We Kim; Gary Richardson; Nicolas Girard; Rachel E. Sanborn; Aaron S. Mansfield; Keunchil Park; Julia Schuchard; Joris Diels; Jan Sermon; Archan Bhattacharya; Patricia Lorenzini; Honeylet Wortman-Vayn; Roland E. Knoblauch; Trishala Agrawal; Mahadi Baig; Akira Ono; Joshua K. Sabari
Amivantamab Plus Chemotherapy in Japanese Patients With EGFR Exon 20 Insertions NSCLC

Amivantamab联合化疗在日本EGFR外显子20插入突变非小细胞肺癌患者中的应用

Cancer Science
IF4.3
2025-09-080
OAAI
Satoru Kitazono; Akira Ono; Tetsuji Kawamura; Osamu Hataji; Hiroshi Tanaka; Shingo Matsumoto; Naohiro Watanabe; Hiromi Nagashima; Masahide Oki; Michiko Takahashi; Tomoko Anazawa; Takahiro Shirai; Aimi Yamashita; Honeylet Wortman-Vayn; Archan Bhattacharya; Trishala Agrawal; Mahadi Baig; Roland E. Knoblauch; Hidetoshi Hayashi
Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC

携带EGFR突变型晚期非小细胞肺癌患者使用amivantamab-lazertinib的总体生存率

NEW ENGLAND JOURNAL OF MEDICINE
IF78.5
2025-09-019
PRE
Yang, James Chih-Hsin; Lu, Shun; Hayashi, Hidetoshi; Felip, Enriqueta; Spira, Alexander I.; Girard, Nicolas; Kim, Yu Jung; Lee, Se-Hoon; Ostapenko, Yurii; Danchaivijitr, Pongwut; Liu, Baogang; Alip, Adlinda; Korbenfeld, Ernesto; Mourao Dias, Josiane; Besse, Benjamin; Passaro, Antonio; Lee, Ki-Hyeong; Xiong, Hailin; How, Soon-Hin; Cheng, Ying; Chang, Gee-Chen; Yoshioka, Hiroshige; Thomas, Michael; Nguyen, Danny; Ou, Sai-Hong Ignatius; Mukhedkar, Sanjay; Prabhash, Kumar; D'Arcangelo, Manolo; Alatorre-Alexander, Jorge; Vazquez Limon, Juan Carlos; Alves, Sara; Stroyakovskiy, Daniil; Peregudova, Marina; Sendur, Mehmet Ali Nahit; Yazici, Ozan; Califano, Raffaele; Gutierrez Calderon, Vanesa; de Marinis, Filippo; Kim, Sang-We; Gadgeel, Shirish M.; Owen, Scott; Xie, John; Sun, Tao; Mehta, Jaydeep; Venkatasubramanian, Raja; Ennis, Mariah; Fennema, Elizabeth; Daksh, Mahesh; Roshak, Amy; Man, Julie; Knoblauch, Roland E.; Bauml, Joshua M.; Baig, Mahadi; Shah, Sujay; Sethi, Seema; Cho, Byoung Chul
Lazertinib Versus Osimertinib in Previously Untreated EGFR-mutant Advanced NSCLC: A Randomized, Double-blind, Exploratory Analysis From MARIPOSA

拉泽替尼与奥希替尼在先前未经治疗的EGFR突变晚期NSCLC中的比较: 来自MARIPOSA的随机，双盲，探索性分析

Journal of Thoracic Oncology
IF20.8
2025-07-030
OAAI
Se-Hoon Lee; Shun Lu; Hidetoshi Hayashi; Enriqueta Felip; Alexander I. Spira; Nicolas Girard; Yu Jung Kim; Yurii Ostapenko; Pongwut Danchaivijitr; Baogang Liu; Adlinda Alip; Ernesto Korbenfeld; Josiane Mourão Dias; Ki Hyeong Lee; Hailin Xiong; Soon Hin How; Ying Cheng; Gee-Chen Chang; James Chih-Hsin Yang; Benjamin Besse; Michael Thomas; Sujay Shah; Mahadi Baig; Joshua C. Curtin; Jiarui Zhang; John Xie; Tao Sun; Seema Sethi; Miao Wang; Elizabeth Fennema; Mahesh Daksh; Mariah Ennis; Joshua M. Bauml; Byoung Chul Cho
Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study

Amivantamab在晚期NSCLC和MET外显子14跳跃突变参与者中的应用: CHRYSALIS研究的最终结果

Journal of Thoracic Oncology
IF20.8
2025-05-160
PREAI
Matthew G. Krebs; Byoung Chul Cho; Sandrine Hiret; Ji-Youn Han; Ki Hyeong Lee; Casilda Llácer Pérez; Filippo De Braud; Eric B. Haura; Rachel E. Sanborn; James Chih-Hsin Yang; Catherine A. Shu; Koichi Goto; Makoto Nishio; Jun Zhao; Zhijie Wang; Pascale Tomasini; Enriqueta Felip; Jonathan W. Goldman; Sai-Hong Ignatius Ou; Michael Boyer; Grace Gao; Siyang Qu; Joshua C. Curtin; Xuesong Lyu; Robert W. Schnepp; Priya Kim; Meena Thayu; Roland E. Knoblauch; Patricia Lorenzini; Mahadi Baig; Alexander I. Spira; Natasha B. Leighl
Cross-over adjusted overall survival for amivantamab plus chemotherapy vs chemotherapy in first-line EGFR exon-20 insertion NSCLC

与化疗相比，阿曼曲妥珠单抗联合化疗在一线EGFR外显子20插入性非小细胞肺癌中的交叉校正总生存期

ANNALS OF ONCOLOGY
IF65.4
2024-12-011
PRE
Lu, S.; Zhou, C.; Cho, B. C.; Ono, A.; Hayashi, H.; Majem, M.; Lee, S-H.; Richardson, G.; Sabari, J. K.; Girard, N.; Sanborn, R. E.; Mansfield, A. S.; Buyukkaramikli, N.; Perualila, N.; Acharya, S.; Chandler, C.; Dearden, L.; Agrawal, T.; Baig, M.; Park, K.
Comparing subcutaneous vs intravenous amivantamab with lazertinib in EGFR-mutated advanced NSCLC: Analysis of Asian patients from PALOMA-3

比较皮下注射与静脉注射阿曼曲单抗联合拉泽替尼在EGFR突变晚期NSCLC中的疗效：PALOMA-3研究中亚洲患者分析

ANNALS OF ONCOLOGY
IF65.4
2024-12-010
PRE
Lee, S-H.; Akamatsu, H.; Yang, J. C-H.; Lim, S. M.; Liu, B.; John, T.; Wang, J.; Ohe, Y.; Kondo, M.; Tamiya, M.; Danchaivijitr, P.; Hsu, P-C.; Zhuo, J.; Saadoun, C.; Saxena, N.; Balaburski, G.; Ribeiro, L.; Gamil, M.; Baig, M.; Cheng, Y.
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC

Amivantamab联合Lazertinib治疗先前未经治疗的EGFR突变的晚期NSCLC

NEW ENGLAND JOURNAL OF MEDICINE
IF78.5
2024-10-2425
PRE
Cho, Byoung C.; Lu, Shun; Felip, Enriqueta; Spira, Alexander I.; Girard, Nicolas; Lee, Jong-Seok; Lee, Se-Hoon; Ostapenko, Yurii; Danchaivijitr, Pongwut; Liu, Baogang; Alip, Adlinda; Korbenfeld, Ernesto; Mourao Dias, Josiane; Besse, Benjamin; Lee, Ki-Hyeong; Xiong, Hailin; How, Soon-Hin; Cheng, Ying; Chang, Gee-Chen; Yoshioka, Hiroshige; Yang, James C. -H.; Thomas, Michael; Nguyen, Danny; Ou, Sai-Hong I.; Mukhedkar, Sanjay; Prabhash, Kumar; D'Arcangelo, Manolo; Alatorre-Alexander, Jorge; Vazquez Limon, Juan C.; Alves, Sara; Stroyakovskiy, Daniil; Peregudova, Marina; Sendur, Mehmet A. N.; Yazici, Ozan; Califano, Raffaele; Gutierrez Calderon, Vanesa; de Marinis, Filippo; Passaro, Antonio; Kim, Sang-We; Gadgeel, Shirish M.; Xie, John; Sun, Tao; Martinez, Melissa; Ennis, Mariah; Fennema, Elizabeth; Daksh, Mahesh; Millington, Dawn; Leconte, Isabelle; Iwasawa, Ryota; Lorenzini, Patricia; Baig, Mahadi; Shah, Sujay; Bauml, Joshua M.; Shreeve, S. Martin; Sethi, Seema; Knoblauch, Roland E.; Hayashi, Hidetoshi
Amivantamab in wild-type advanced non-small cell lung cancer after disease progression on checkpoint inhibition and chemotherapy: Results from the phase 1b CHRYSALIS study
CANCER RESEARCH
IF16.6
2024-04-050
PRE
Cho, Byoung Chul; Goldman, Jonathan; Leighl, Natasha; De Braud, Filippo; Lee, Ki Hyeong; Ghiringhelli, Francois; Garrido, Pilar; Peguero, Julio; Besse, Benjamin; Cassier, Philippe; Girard, Nicolas; de Miguel, Maria; Alvarez, Rosa; Greystroke, Alastair; Ohe, Yuichiro; Hsia, Te-Chun; Curtin, Joshua C.; Chowdhury, Sanjib; Lyu, Xuesong; Gao, Grace; Qu, Siyang; Lorenzini, Patricia; Kapoor, Aastha; Kim, Priya; Baig, Mahadi; Thayu, Meena; Knoblauch, Roland E.; Hiret, Sandrine; Tomasini, Pascale
Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer

厄达替尼在卡介苗治疗的高危非肌层浸润性膀胱癌中的应用

ANNALS OF ONCOLOGY
IF65.4
2024-01-0121
OA
Catto, J. W. F.; Tran, B.; Roupret, M.; Gschwend, J. E.; Loriot, Y.; Nishiyama, H.; Redorta, J. P.; Daneshmand, S.; Hussain, S. A.; Cutuli, H. J.; Procopio, G.; Guadalupi, V.; Vasdev, N.; Naini, V.; Crow, L.; Triantos, S.; Baig, M.; Steinberg, G.
THOR-2 cohort 1: Results of erdafitinib (ERDA) vs intravesical chemotherapy (chemo) in patients (pts) with high-risk non emuscle-invasive bladder cancer (HR NMIBC) with select fibroblast growth factor receptor alterations (FGFRALT) who received prior bacillus calmette-guerin (BCG) treatment
ANNALS OF ONCOLOGY
IF65.4
2023-10-010
PRE
Catto, J. W. F.; Tran, B.; Roupret, M.; Gschwend, J. E.; Loriot, Y.; Nishiyama, H.; Palou, J.; Daneshmand, S.; Hussain, S. A.; Cutuli, H. J.; Procopio, G.; Guadalupi, V.; Vasdev, N.; Naini, V.; Crow, L.; Triantos, S.; Baig, M.; Steinberg, G. D.

研究方向

暂未获取到该数据
B
Byoung Chul Cho
H 指数:106论文数:1,592被引数:7.0万
R
Roland E. Knoblauch
H 指数:28论文数:166被引数:4,589
A
Akira Ono
H 指数:36论文数:296被引数:4,787
H
Hidetoshi Hayashi
H 指数:53论文数:645被引数:1.3万
J
John Xie
H 指数:24论文数:70被引数:4,392
S
Sujay Shah
H 指数:5论文数:22被引数:2,366
T
Trishala Agrawal
H 指数:3论文数:20被引数:345
P
Pongwut Danchaivijitr
H 指数:18论文数:80被引数:5,477
J
Joshua Bauml
H 指数:41论文数:260被引数:8,111
S
Se-Hoon Lee
H 指数:6论文数:84被引数:642